Valuation
- Market cap
- 2,200,891,000
- Revenue TTM
- $0
- Net income TTM
- $-367,080,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.07
Trading
- Volume
- 55,645,300
- Avg volume
- 6,452,184
- Day's range
- $14.82 – $14.87
- Shares out
- 148,308,000
- Stochastic %K
- 77%
- Beta
- 1.27
- Analysts
- Moderate Buy
- Price target
- $31.64
Company profile
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly known as The company wa...
Show more
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly known as The company was founded in 2018 and is based in San Francisco, California. As of October 29, 2025, 89bio, Inc. operates as a subsidiary of Roche Holding AG.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 415 432 9270
- Website
- https://www.89bio.com
- Address
- 655 Montgomery Street, Suite 1500, San Francisco, United States
Latest news
No headlines yet.
